Rockefeller Financial Services’s BioMarin Pharmaceuticals BMRN Stock Holding History

Rockefeller Financial Services’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-1,421	Closed	-$111K	–	463
2016 Q2	$111K	Buy	+1,421	New	+$121K	﹤0.01%	350
2015 Q3	–	Sell	-2,126	Closed	-$291K	–	513
2015 Q2	$291K	Sell	2,126 -1,429	-40%	-$177K	0.01%	282
2015 Q1	$443K	Sell	3,555 -220	-6%	-$23.3K	0.01%	257
2014 Q4	$341K	Sell	3,775 -310	-8%	-$25.8K	0.01%	269
2014 Q3	$295K	Buy	+4,085	New	+$268K	0.01%	295
2014 Q1	–	Sell	-409,644	Closed	-$28.8M	–	510
2013 Q4	$28.8M	Sell	409,644 -19,176	-4%	-$1.3M	0.62%	50
2013 Q3	$30.9M	Sell	428,820 -74,932	-15%	-$4.98M	0.72%	49
2013 Q2	$28.1M	Buy	+503,752	New	+$31.4M	0.67%	48

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Rockefeller Financial Services's BMRN Position: Q3 2016 in Review

Rockefeller Financial Services sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2016, closing a stake of 1,421 shares — an estimated $111K sold.

Rockefeller Financial Services first reported a position in BMRN in Q2 2013 and held it in 8 quarters. The position peaked at $30.9M in Q3 2013. 424 funds tracked by Wall St. Rank hold BMRN as of Q3 2016.

Rockefeller Financial Services reported no remaining BioMarin Pharmaceuticals position as of Q3 2016 after selling out during the quarter.
Rockefeller Financial Services sold 1,421 BioMarin Pharmaceuticals shares in Q3 2016, an estimated $111K.
Rockefeller Financial Services first reported a position in BioMarin Pharmaceuticals in Q2 2013 and held it in 8 quarters.
Rockefeller Financial Services's BioMarin Pharmaceuticals position peaked at $30.9M in Q3 2013.
424 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2016.

Based on Rockefeller Financial Services's 13F filing for Q3 2016, filed 28 Oct 2016.